Catalyst grants Kye exclusive Canadian rights to AGAMREE for DMD

CATALYST PHARMACEUTICALS, INC.

Kye Pharmaceuticals gets exclusive Canadian rights to commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy.
Catalyst will supply product; Kye responsible for Health Canada approval and all commercialization in Canada.
Catalyst receives upfront payment, plus potential reimbursement, sales milestones, and royalties from Kye.
Kye already markets Catalyst's FIRDAPSE in Canada; AGAMREE application to Health Canada expected by early 2025.
Agreement expands AGAMREE's North American footprint beyond U.S. approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.